TORONTO, ON, January 11, 2024 – LifeLabs, Canada’s leading diagnostic testing services and recognized as the most trusted brand in health diagnostic services by Canadians, proudly announces an exclusive partnership with Klinrisk, a Canadian AI-based medical device company focused on improving early detection and treatment of chronic kidney disease (CKD) through the groundbreaking Klinrisk Score.
Available now at LifeLabs in Ontario, the Klinrisk test analyzes routine blood and urine samples and delivers a comprehensive report indicating the risk of progression for kidney function loss of up to 40% or kidney failure in the next five years. Risk categories and recommendations are provided to alert customers and healthcare providers to complications of kidney disease and associated care pathways recommended by clinical practice guidelines.
“LifeLabs partnership with Klinrisk aligns seamlessly with our mission to empower customers to take control and manage their health journey effectively,” said Lawrence Mahan, Sr. VP of Business & Consumer Markets at LifeLabs. “The Klinrisk provides healthcare providers and customers with invaluable insights for early intervention.”
Klinrisk echoes this sentiment: “We are delighted to partner with LifeLabs to bring the Klinrisk model to Canada for people with or at risk for chronic kidney disease,” said Dr. Navdeep Tangri, President and Scientific founder of Klinrisk Inc., “Progression of CKD is now completely preventable, but the key is early recognition. The Klinrisk test enables recognition of high risk early in the patient journey before kidney function is lost.”
Dr. Pablo Pergola, a Nephrologist and Clinical Trialist at Renal Associates San Antonio TX, attests to the impact: “Klinrisk gives me a clear line of sight on the highest risk patients in my practice, these are patients that need us, and the therapies that we can offer the most.”
For more information on the Klinrisk Score and how it transforms CKD care, visit www.lifelabs.com/test/klinrisk-score/